BC Innovations | Oct 3, 2019
Targets & Mechanisms

ALS platform trial to put neuroinflammation hypothesis to the test

The largest test of the idea that ALS is driven by neuroinflammation will come from the first collaborative platform trial in the disease, which could blow open the range of pathways and targets in play...
BC Extra | Sep 27, 2019
Clinical News

Avanir’s Alzheimer’s miss weighs on Concert shares

Concert fell 37% on Friday after its partner Avanir reported that AVP-786 missed its primary endpoint and key secondary endpoints in a Phase III trial for mild to severe agitation in patients with Alzheimer's dementia....
BC Week In Review | Aug 17, 2015
Clinical News

Nuedexta dextromethorphan/quinidine: Phase IV data

Top-line data from the open-label, U.S. Phase IV PRISM II trial in 367 patients with PBA showed that twice-daily 20/10 mg Nuedexta reduced mean CNS-LS score to 11.9 points at week 12 from 20.5 points...
BioCentury | Jan 12, 2015

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
BioCentury | Dec 15, 2014

Avanir Chronicles

Avanir Chronicles Avanir chroniclesThe $17 takeout price Otsuka Pharmaceutical Co. Ltd. will pay for Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) is only a 13% premium to the neurology play's close the day before the $3.5 billion deal...
BC Week In Review | Dec 8, 2014
Company News

Avanir, Otsuka Pharmaceutical deal

Otsuka is acquiring Avanir for $17 per share in a deal valued at about $3.5 billion. The price represents a 13% premium to Avanir’s closing price of $15 on Dec. 1, before the deal was...
BC Extra | Dec 3, 2014
Top Story

Otsuka buying Avanir for $3.5B

Otsuka Pharmaceutical Co. Ltd. (Tokyo, Japan) will acquire Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) for $3.5 billion, or $17 per share. The price represents a 13% premium to Avanir's closing price of $15 on Dec. 1 before...
BC Week In Review | Oct 20, 2014
Clinical News

Nuedexta dextromethorphan/quinidine: Additional Phase II data

Additional data from 218 AD patients in the modified intent-to-treat (mITT) population of the 10-week, double-blind, U.S. Phase II AVR-131 trial showed that oral AVP-923 significantly reduced agitation as measured by the agitation/aggression subscale score...
BioCentury | Oct 6, 2014

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
BC Extra | Sep 25, 2014
Financial News

Avanir raises $200.2M follow-on

Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) raised $200.2 million through the sale of 18.2 million shares at $11 in a follow-on underwritten by J.P. Morgan; Deutsche Bank; and BofA Merrill Lynch. Avanir said Monday it planned to...
Items per page:
1 - 10 of 194